Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹208 Cr
up ₹16.3 Cr vs Aug 2014
- Stocks held
- 25
- unchanged
- Top 10 weight
- 76.6%
- of the portfolio in its ten largest
- Cash & debt
- 7.1%
- cash, money market and debt
- Moves this month
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In September 2014 it disclosed 25 stocks worth ₹208 Cr, up ₹16.3 Cr from Aug 2014. Its largest positions were Sun Pharmaceutical Industries Limited (18.4%), Dr. Reddy's Laboratories Limited (15.1%), Lupin Limited (12.3%); the ten largest together made up 76.6% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 85.2% of its equity. Cash and debt stood at 7.1%. Compared with Aug 2014 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
85%
Holds more cash than 85% of peers
What these mean: concentration · cash
Holdings in September 2014
Download CSVEvery line the fund disclosed, with the change against Aug 2014. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 18.43% | down 6.23 pts | ₹38.3 Cr | down ₹8.9 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 15.08% | up 0.14 pts | ₹31.3 Cr | up ₹2.7 Cr | Added |
| Lupin Limited | 12.26% | up <0.01 pts | ₹25.5 Cr | up ₹2 Cr | Added |
| Cipla Limited | 10.60% | up 1.16 pts | ₹22 Cr | up ₹4 Cr | Added |
| Cash, TREPS & receivables | 7.15% | up 5.06 pts | ₹14.8 Cr | up ₹10.8 Cr | Added |
| Divi's Laboratories Limited | 4.98% | up 0.28 pts | ₹10.3 Cr | up ₹1.4 Cr | Added |
| Ranbaxy Laboratories Ltd | 4.59% | down 0.40 pts | ₹9.5 Cr | down ₹1 L | Held |
| Biocon Limited | 3.08% | down 0.03 pts | ₹6.4 Cr | up ₹44 L | Added |
| Aurobindo Pharma Limited | 2.97% | up 0.25 pts | ₹6.2 Cr | up ₹96 L | Added |
| Glenmark Pharmaceuticals Limited | 2.46% | down 0.19 pts | ₹5.1 Cr | up ₹3 L | Added |
| Wyeth Ltd | 2.16% | up 0.04 pts | ₹4.5 Cr | up ₹43 L | Added |
| Indoco Remedies Limited | 1.94% | up 0.07 pts | ₹4 Cr | up ₹46 L | Added |
| Strides Pharma Science Limited | 1.81% | up <0.01 pts | ₹3.8 Cr | up ₹30 L | Added |
| Sun Pharma Advanced Research Company Limited | 1.68% | down 0.12 pts | ₹3.5 Cr | up ₹4 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 1.67% | up 0.07 pts | ₹3.5 Cr | up ₹42 L | Added |
| IPCA Laboratories Limited | 1.62% | down 0.04 pts | ₹3.4 Cr | up ₹19 L | Added |
| Zydus Lifesciences Limited | 1.29% | up 0.02 pts | ₹2.7 Cr | up ₹25 L | Added |
| Natco Pharma Limited | 1.08% | up 0.11 pts | ₹2.2 Cr | up ₹38 L | Added |
| Piramal Enterprises Limited | 0.97% | up 0.02 pts | ₹2 Cr | up ₹20 L | Added |
| Sanofi India Limited | 0.96% | down 0.01 pts | ₹2 Cr | up ₹13 L | Added |
| SHASUN PHARMACEUTICALS LTD. | 0.93% | down 0.18 pts | ₹1.9 Cr | down ₹20 L | Trimmed |
| Unichem Laboratories Limited | 0.83% | down 0.07 pts | ₹1.7 Cr | down ₹0 L | Held |
| Torrent Pharmaceuticals Limited | 0.58% | down 0.02 pts | ₹1.2 Cr | up ₹5 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.51% | up 0.05 pts | ₹1.1 Cr | up ₹18 L | Added |
| Shilpa Medicare Limited | 0.19% | up <0.01 pts | ₹40 L | up ₹3 L | Added |
| Pfizer Limited | 0.17% | up 0.01 pts | ₹36 L | up ₹5 L | Added |
What changed, Aug 2014 to Sep 2014
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Cipla Limitedup ₹4 Cr (+1.16% pts)
- Dr. Reddy's Laboratories Limitedup ₹2.7 Cr (+0.14% pts)
- Lupin Limitedup ₹2 Cr (+<0.01% pts)
- Divi's Laboratories Limitedup ₹1.4 Cr (+0.28% pts)
- Aurobindo Pharma Limitedup ₹96 L (+0.25% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Aug 2014, the weight rose most in Pharmaceuticals (+0.2 pts), and fell most in Pharmaceuticals & Biotechnology (−0.3 pts).
- Pharmaceuticals13.5% → 13.8%+0.2 pts
- Pharmaceuticals & Biotechnology85.5% → 85.2%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Mar 2014 | Jun 2014 | Aug 2014 | Sep 2014 |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 90.5% | 86.8% | 85.5% | 85.2% |
| Pharmaceuticals | 8.4% | 12.1% | 13.5% | 13.8% |
| Finance | 1.1% | 1.1% | 1.0% | 1.0% |
Allocation in Sep 2014change vs Aug 2014
- Pharmaceuticals & Biotechnology (17)85.2%▼ 0.3 pts
- Pharmaceuticals (7)13.8%▲ 0.2 pts
- Finance (1)1.0%▲ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2014
7.1%
▲ 5.1 pts vs Aug 2014
- Cash alone
- 7.1%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 2.1% – 11.6%
- lowest to highest · record 11.6% in Mar 2014
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.